4 citations
,
October 2024 in “American Journal of Clinical Dermatology” This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.
June 2026 in “Clinical and Experimental Dermatology” This review identified various outcome measure instruments for assessing androgenetic alopecia but found inconsistent application across clinical trials, underscoring the need for standardized assessment methods.
11 citations
,
March 2021 in “Dermatology and therapy” This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.
1 citations
,
January 2025 in “JEADV Clinical Practice” This study reported that the AAPPO tool effectively distinguishes between patients with alopecia areata based on scalp hair loss severity, whereas the EQ‐5D‐5L may underestimate the specific disease burden, particularly in psychological and social aspects.
May 2011 in “Value in Health” This review assessed patient-reported outcome measures for alopecia treatments but found that none met current FDA guidelines; however, some could potentially be adapted for more comprehensive use.